{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:48:58Z","timestamp":1773701338936,"version":"3.50.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSAMC"],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Alzheimer\u2019s disease, an extremely prevalent neurological illness and the leading cause\nof dementia globally, is an extremely prevalent neurological illness and is the leading cause of dementia globally. There are a few treatment options for AD, and those that do exist only slightly reduce symptoms, even after several clinical studies. The formation of A\u03b2 plaques, neuroinflammation, and hyperphosphorylated tau neurofibrillary tangles are the characteristics of AD. While\nmonoclonal antibodies such as lecanemab, donanemab, and aducanumab have demonstrated potential in addressing A\u03b2, their clinical efficacy and safety over an extended period of time remain uncertain. Novel avenues for tackling the underlying genetic causes of AD have been made possible\nby developments in genome editing tools, most notably CRISPR-Cas9. In preclinical animals,\nCRISPR-Cas9 has effectively edited genes relevant to AD, such as APP and PSEN1, leading to decreased levels of A\u03b2 and enhanced cognitive function. Additionally, base and prime editing, two\nprecision gene-editing techniques, have increased the medicines' selectivity and decreased their offtarget effects. However, before clinical applications are deployed, challenges related to technology,\nethics, and safety must be resolved. This review highlights how monoclonal antibodies, neuroinflammation research, and CRISPR-Cas9 have the potential to revolutionize therapy choices for AD\nby examining the most current developments in the field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0118715249403872251208145159","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:29:21Z","timestamp":1773286161000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Therapies and Research in Alzheimer's Disease: A Critical\nReview"],"prefix":"10.2174","volume":"26","author":[{"given":"Madan Mohan","family":"Agrawal","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Chandigarh University, Mohali, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payal","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Chandigarh University, Mohali, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Central Nervous System Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715249403872251208145159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/250620\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715249403872251208145159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:29:53Z","timestamp":1773286193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/250620\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715249403872251208145159","relation":{},"ISSN":["1871-5249"],"issn-type":[{"value":"1871-5249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}